NIVALENOL AS SPECIFIC INHIBITOR TO TRANSCRIPTIONAL FACTOR C-MAF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME

摘要

The present invention relates to a pharmaceutical composition for treatment or prophylaxis of Th2 cytokine-related diseases, which comprises a a pharmaceutically effective dose of nivalenol as an inhibitor for the activity of IL-4, especially via c-Maf transcription factor inhibition, and b a pharmaceutically acceptable carrier.